A phase III study of Calmangafodipir (PledOx®) in patients with metastatic colorectal cancer

Trial Profile

A phase III study of Calmangafodipir (PledOx®) in patients with metastatic colorectal cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Calmangafodipir (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2016 According to a PledPharma media release, top-line results from the study are anticipated in the year 2020.
    • 20 Oct 2016 According to a PledPharma media release, this trial will form the basis for a new drug application (NDA) to the Food and Drug Administration (FDA) in the US and for a marketing authorization application (MAA) to the European Medicines Agency (EMA) in Europe.
    • 13 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top